B. Timothy Hummer

1 month ago | pubs.acs.org | B. Timothy Hummer |Jiaqi Yuan |Yue Huang |Meina Liang

MEDI7219 is a bis-lipidated glucagon-like peptide-1 (GLP-1) analog with enhanced systemic circulation time due to increased reversible binding to albumin. It was being developed as an oral formulation to improve glycemic control and body weight loss in patients with Type 2 diabetes. (1,2) Currently, most GLP-1 receptor agonists are administered via subcutaneous (SC) injection. Thus, oral administration of MEDI7219 may provide a better option for patients by increasing compliance and ease-of-use.